Development of EndoScreen chip, a microfluidic pre-endoscopy triage test for esophageal adenocarcinoma
| Autor: | Karthik Balaji Shanmugasundaram, B. Paul Morgan, Alain Wuethrich, Louisa G. Gordon, Wioleta M. Zelek, Matt Trau, Michelle M. Hill, Bradley J. Kendall, Gunter Hartel, Renee S. Richards, Alok K. Shah, Julie A. Webster |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
glycoprotein
0301 basic medicine Cancer Research medicine.medical_specialty Gastroenterology Article 03 medical and health sciences 0302 clinical medicine Internal medicine Biopsy medicine Barrett’s esophagus Multiplex Esophagus Liquid biopsy RC254-282 2. Zero hunger complement component liquid biopsy medicine.diagnostic_test SERS business.industry screening Neoplasms. Tumors. Oncology. Including cancer and carcinogens Heartburn medicine.disease surface-enhanced Raman spectroscopy 3. Good health 030104 developmental biology medicine.anatomical_structure Oncology Barrett's esophagus Immunoassay surveillance lectin biomarker Biomarker (medicine) 030211 gastroenterology & hepatology medicine.symptom business |
| Zdroj: | Cancers, Vol 13, Iss 2865, p 2865 (2021) Cancers Volume 13 Issue 12 |
| ISSN: | 2072-6694 |
| Popis: | The current endoscopy and biopsy diagnosis of esophageal adenocarcinoma (EAC) and its premalignant condition Barrett’s esophagus (BE) is not cost-effective. To enable EAC screening and patient triaging for endoscopy, we developed a microfluidic lectin immunoassay, the EndoScreen Chip, which allows sensitive multiplex serum biomarker measurements. Here, we report the proof-of-concept deployment for the EAC biomarker Jacalin lectin binding complement C9 (JAC-C9), which we previously discovered and validated by mass spectrometry. A monoclonal C9 antibody (m26 3C9) was generated and validated in microplate ELISA, and then deployed for JAC-C9 measurement on EndoScreen Chip. Cohort evaluation (n = 46) confirmed the expected elevation of serum JAC-C9 in EAC, along with elevated total serum C9 level. Next, we asked if the small panel of serum biomarkers improves detection of EAC in this cohort when used in conjunction with patient risk factors (age, body mass index and heartburn history). Using logistic regression modeling, we found that serum C9 and JAC-C9 significantly improved EAC prediction from AUROC of 0.838 to 0.931, with JAC-C9 strongly predictive of EAC (vs. BE OR = 4.6, 95% CI: 1.6–15.6, p = 0.014 vs. Healthy OR = 4.1, 95% CI: 1.2–13.7, p = 0.024). This proof-of-concept study confirms the microfluidic EndoScreen Chip technology and supports the potential utility of blood biomarkers in improving triaging for diagnostic endoscopy. Future work will expand the number of markers on EndoScreen Chip from our list of validated EAC biomarkers. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|